Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, discusses treatment strategies for chronic lymphocytic leukemia (CLL) in the frontline setting, which currently include continuous treatment with BTK inhibitors, or fixed-duration venetoclax plus obinutuzumab. Dr Patel highlights that trials for combination therapies are producing promising data, and approaches to define optimal treatment duration based on MRD status are being evaluated. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.